



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/025,195
		Filing Date	December 19, 2001
		First Named Inventor	David Berd
		Art Unit	1642
		Examiner Name	Brandon Fetterolf
Sheet 1	of 1	Attorney Docket Number	061266-5009-02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		A. BODURTHA et al., "A clinical, histologic, and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission." Cancer 37: 735-42, 1976.	
/B.F./		D. ELDER et al., "The surgical pathology of cutaneous malignant melanoma." Human Malignant Melanoma, edited by WH CLARK et al. New York: Grune & Stratton; 1979, p. 55-108	
/B.F./		E. CREAGAN et al., "Recombinant leukocyte A interferon in the treatment of disseminated malignant melanoma." Cancer 58: 2576-1578, 1986.	
/B.F./		T. EVERSON et al., "Spontaneous regression of cancer." Philadelphia: W.B. Saunders Company; 1966.	
/B.F./		J. HARRIS et al., "Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine." J Clin Oncol, Vol 18:1, 2000; pp. 148-157	
/B.F./		S. ROSENBERG, "Progress in human tumour immunology and immunotherapy." Nature, 2001 May 17; Vol 411: 380-4.	
/B.F./		J VERMORKEN et al., "Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial." Lancet 1999; 353: 345-50.	

Examiner Signature	/Brandon Fetterolf/	Date Considered	06/02/2008
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.